Relationship between LAPTM4B gene polymorphism and susceptibility of primary liver cancer

Annals of Oncology

Volumn 23, Issue 7, 2012, Pages 1864-1869

  Wang, S ^a   Zhang, Q Y ^a   Zhou, R L ^b  

^a PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Gene polymorphism; LAPTM4B; Primary liver cancer; Susceptibility

Indexed keywords

GENOMIC DNA;

ADULT; ARTICLE; CANCER CLASSIFICATION; CANCER RISK; CANCER SUSCEPTIBILITY; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPING TECHNIQUE; HUMAN; LIVER CANCER; LYSOSOME ASSOCIATED PROTEIN TRANSMEMBRANE 4 BETA GENE; MAJOR CLINICAL STUDY; MALE; MOLECULAR PATHOLOGY; ONCOGENE; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR;

EID: 84859233273     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr538     Document Type: Article

References (29)

1. Schutte K, Bornschein J, Malfertheiner P. Hepatocellular carcinoma- epidemiological trends and risk factors. Epidemiology and Pathomechanisims 2009; 27: 80-92.
2. Sangiovanni A, Del Ninno E, Fasani P et al. Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology 2004; 126: 1005-1014.
3. Parkin M, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
4. Francesco F, Maddalena F, Maria L et al. Genetic and epigenetic control of molecular alterations in hepatocellular carcinoma. Biol Med 2009; 234: 726-736.
5. World Health Organization. Mortality Database. WHO Statistical Information System. http://www.who.int/whosis.
6. Yuen MF, Hou JL, Chutaputti A. on behalf of the Asia Pacific Working Party on Prevention of Hepatocellular Carcinoma. Hepatocellular carcinoma in the Asia pacific region. J Gastroenterol Hepatol 2009; 24: 346-353.
7. Shao GZ, Zhou RL, Zhang QY et al. Molecular cloning and characterization of LAPTM4B, a novel gene upregulated in hepatocellular carcinoma. Oncogene 2003; 22: 5060-5069.
8. Liu Y, Zhang Q-Y, Qian N et al. Relationship between LAPTM4B gene polymorphism and susceptibility of gastric cancer. Ann Oncol 2007; 18: 311-316.
9. Maeda K, Horikoshi T, Nakashima E et al. MATN and LAPTM are parts of larger transcription units produced by intergenic splicing: intergenic splicing may be a common phenomenon. DNA Res 2005; 12: 365-372.
10. Kasper G, Vogel A, Klaman I et al. The human LAPTM4b transcript is upregulated in various types of solid tumors and seems to play a dual functional role during tumor progression. Cancer Lett 2005; 224: 93-103.
11. Rui J-A, Ye DX. Structure analysis and expressions of a novel tetratransmembrane protein, lysosome-associated protein transmembrane 4B associated with hepatocellular carcinoma. World J Gastroenterol 2004; 10(11): 1555-1559.
12. Liu JJ, Zhang J, Zhou RL et al. Partial cloning of LHS cDNA and effect of its expression on behavior of hepatocellular carcinoma cells. J Beijing Med Univ 2000; 32: 526-529.
13. Liu XR, Zhou RL, Zhang QY et al. Identification and characterization of LAPTM4B encoded by a human hepatocellular carcinoma-associated novel gene. Beijing Da Xue Xue Bao 2003; 35: 340-347.
14. He J, Shao GZ, Zhou RL. Effects of the novel gene, LAPTM4B highly expression in hepatocellular carcinoma on cell proliferation and tumourigenesis of NIH3T3. Beijing Da Xue Xue Bao 2003; 35: 348-352.
15. Peng C, Zhou RL, Shao GZ et al. Expression of lysosome-associated protein transmembrane 4B-35 in cancer and its correlation with the differentiation status of hepatocellular carcinoma. World J Gastroenterol 2005; 11: 2704-2708.
16. Yang H, Xiong FX, Lin M et al. LAPTM4B-35 overexpression is a risk factor for tumor recurrence and poor prognosis in hepatocellular carcinoma. J Cancer Res Clin Oncol 2010; 136(2): 275-281.
17. Yang Y, Yang H, Xiong F et al. LAPTM4B overexpression is an independent prognostic marker in ovarian carcinoma. Oncol Rep 2008; 20(5): 1077-1083.
18. Zhou L, He XD, Cui QC et al. Expression of LAPTM4B-35: a novel marker of progression, invasiveness and poor prognosis of extrahepatic cholangiocarcinoma. Cancer Lett 2008; 264: 209-217.
19. Meng FL, Yin MZ, Song HT. LAPTM4B-35 overexpression is an independent prognostic marker in endometrial carcinoma. Int J Gynecol Cancer 2010; 20: 745-750.
20. Yang H, Xiong F, Wei X et al. Overexpression of LAPTM4B-35 promotes growth and metastasis of hepatocellular carcinoma in vitro and in vivo. Cancer Lett 2010; 294: 236-244.
21. Yin M, Xu Y, Lou G et al. LAPTM4B overexpression is a novel predictor of epithelial ovarian carcinoma metastasis. Int J Cancer 2010; 129: 629-635.
22. Deng LJ, Zhang QY, Liu B et al. Relationship between LAPTM4B gene polymorphism and susceptibility of lung cancer. J Beijing Med Univ 2005; 37(3): 302-305.
23. Sun L, Zhang QY, Liu Y, Qian N. Relationship between LAPTM4B gene polymorphism and susceptibility of lymphoma. Cancer Research on Prevention and Treatment 2007; 34(4): 245-248.
24. Cheng XJ, Xu W, Zhang QY, Zhou RL. Relationship between LAPTM4B gene polymorphism and susceptibility of colorectal and esophageal cancers. Ann Oncol 2008; 19: 527-532.
25. Meng F, Song H, Luo C et al. Correlation of LAPTM4B polymorphisms with cervical carcinoma. Cancer 2011; 117(12): 2652-2658.
26. Xiao Jing C, Qing Yun Z, Rou Li Z. Methylation of LAPTM4B promoter region influences its mRNA expression in esophageal cancer. Zhongguo Sheng Wu Hua Xue Yu Fen Zi Sheng Wu Xue Bao 2008; 24(1): 89-94.
27. Xu F, Paquette AJ, Anderson DJ et al. Identification of a cell type-specific silencer in the first exon of the His-1 gene. J Cell Biochem 2000; 76(4): 615-624.
28. Liu J, Zhou R, Zhang N et al. Biological function of a novel gene overexpressed in human hepatocellular carcinoma. Chin Med J (Engl) 2000; 113: 881-885.
29. Luo R, Zhao Z, Gao Z, Yao J. Risk factors for primary liver carcinoma in Chinese population. World J Gastroenterol 2005; 11: 4431-4434.